Anticalin therapeutic protein - Pieris AG/Daiichi Sankyo

Drug Profile

Anticalin therapeutic protein - Pieris AG/Daiichi Sankyo

Latest Information Update: 23 Dec 2015

Price : $50

At a glance

  • Originator Daiichi Sankyo Company; Pieris
  • Developer Pieris
  • Class Proteins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Unspecified

Most Recent Events

  • 19 Nov 2015 Phase-I clinical trials in Undefined indication in USA (unspecified route)
  • 19 Nov 2015 Daiichi Sankyo initiates enrolment in a phase I trial for an undisclosed indication in USA
  • 18 Apr 2013 Preclinical trials in Undefined indication in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top